Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|11|2442-2447

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.11, 2015-11, pp. : 2442-2447

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 6, 2015-06 ,pp. : 823-830

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 12, 2015-12 ,pp. : 1105-1111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 2, 2015-02 ,pp. : 272-274

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1880-1886

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of simeprevir following pre‐emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12‐week pilot study

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 2, 2015-02 ,pp. : 144-150

John Wiley & Sons Inc

Access to resources Recommend Favorite